

ALZHEIMER'S DISEASE DRUG DEVELOPMENT PIPELINE: 2024

The 2024 pipeline offers hope for a future of new treatments and powerful combination therapies for Alzheimer's disease and all other dementias



In 2024, there are

127 UNIQUE THERAPIES in **164** CLINICAL TRIALS for Alzheimer's disease as registered on clinicaltrials.gov

35 new trials have entered the pipeline in the past year

Therapies in the pipeline

45% of disease-modifying treatments (DMTs) are biologics (a decrease from previous year)

55% of DMTs are small molecules

31% of candidate therapies are repurposed from other diseases

Targets of agents currently in clinical trials include



76% disease modification

12% cognitive enhancement

13% behavioral and neuropsychiatric symptoms

Agents with primary mechanistic targets include



75% novel disease processes

25% amyloid and tau



The total number of participants needed to populate all currently active trials (Phases 1, 2 and 3) is

51,398

Inflammation and transmitters are the most well represented novel themes in the pipeline

PHASE 3 CLINICAL TRIALS



32
agents



48
trials

PHASE 2 CLINICAL TRIALS



81
agents



90
trials

PHASE 1 CLINICAL TRIALS



25
agents



26
trials